Aptalis Holdings Inc. Sustainability Profile
Aptalis Holdings Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2008, the company has established itself as a leader in developing innovative drug delivery systems and specialty pharmaceuticals. With a focus on enhancing patient outcomes, Aptalis operates primarily in North America and Europe, catering to diverse therapeutic areas, including gastrointestinal and respiratory health. The company’s core offerings include advanced formulations and unique delivery technologies that set them apart in a competitive market. Notable achievements include strategic partnerships and a robust pipeline of products that address unmet medical needs. Aptalis Holdings Inc. continues to solidify its market position through a commitment to research and development, driving advancements in patient care and therapeutic efficacy.
DitchCarbon Score
How does Aptalis Holdings Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aptalis Holdings Inc.'s score of 41 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aptalis Holdings Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of AbbVie Inc., which influences its climate commitments and reporting practices. While Aptalis Holdings Inc. does not have its own documented reduction targets, it inherits sustainability initiatives from its parent company, AbbVie Inc. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions in line with global climate goals. As part of its corporate family, Aptalis may also align with broader climate strategies and commitments established by AbbVie, which are designed to enhance environmental performance and accountability. However, specific details regarding Aptalis's individual climate pledges or reduction targets remain unspecified. In summary, while Aptalis Holdings Inc. does not provide direct emissions data or specific reduction targets, it is positioned within a corporate structure that prioritises climate action through inherited initiatives from AbbVie Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 28,218,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 59,189,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Aptalis Holdings Inc.'s Industry?
How Carbon Intensive is Aptalis Holdings Inc.'s Location?
Aptalis Holdings Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aptalis Holdings Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
